What is Natco's revenue guidance for FY27?

Natco is guiding for FY27 revenue of ₹3,400-3,500 crore and a profit after tax (PAT) of ₹700-750 crore.

Is this the first time these numbers have been shared?

No. The financial guidance was previously disseminated through a concall summary filing. This transcript provides the detailed management commentary behind those numbers.

What are the key operational topics discussed?

Management discussed the launch timeline for its Semaglutide product and its strategy for mergers and acquisitions (M&A).

What long-term growth target did management set?

Natco outlined a long-term annual growth outlook of 15-25%.

Earnings · Pharmaceuticals · Mid cap

Natco's FY27 guide stays put: ₹3,400-3,500 cr revenue, ₹700-750 cr PAT

The Q4 call transcript adds detail on Semaglutide and M&A but confirms numbers already guided. The investment thesis is unchanged.

NATCOPHARM By Tipsheet Editorial 4 Jun 2026 · 2:55 PM IST Verify on BSE · NSE

Mkt cap₹16,455 cr

P/E11.60×

ROE24.79%

Debt / eq.0.04

Div yld0.53%

₹3,400-3,500 cr FY27 revenue guidance, reiterated in the transcript.

What's new

Natco's FY27 revenue guidance is ₹3,400-3,500 cr, with a PAT target of ₹700-750 cr.
Management reiterated a long-term annual growth outlook of 15-25%.
The transcript details commentary on the Semaglutide launch and M&A strategy.

Why this matters

This is a transcript, not a new disclosure. The key financial targets were already known from the prior concall summary. For investors, the value lies in the management's tone on execution, particularly the Semaglutide ramp and capital deployment for acquisitions, not in any new numbers.

What we're watching

The pace of the Semaglutide launch and its contribution to FY27 revenue.
Actual M&A deal announcements and their impact on the balance sheet.
Quarterly execution against the ₹3,400-3,500 cr revenue guide.

The full read

Natco Pharma's Q4 earnings call transcript is a record of what management already said. The headline numbers are unchanged: FY27 revenue of ₹3,400-3,500 crore, a PAT target of ₹700-750 crore, and a long-term growth outlook of 15-25% annually. The new detail is in the commentary on execution. Management elaborated on the launch of its Semaglutide product and its approach to M&A, areas where the prior summary offered only a sketch. For an investor, the transcript confirms the financial path. The open questions are operational: how quickly the new drug ramps and where acquisition capital goes.

Questions answered

What is Natco's revenue guidance for FY27?: Natco is guiding for FY27 revenue of ₹3,400-3,500 crore and a profit after tax (PAT) of ₹700-750 crore.
Is this the first time these numbers have been shared?: No. The financial guidance was previously disseminated through a concall summary filing. This transcript provides the detailed management commentary behind those numbers.
What are the key operational topics discussed?: Management discussed the launch timeline for its Semaglutide product and its strategy for mergers and acquisitions (M&A).
What long-term growth target did management set?: Natco outlined a long-term annual growth outlook of 15-25%.

Mentioned: Natco Pharma · Semaglutide · ₹3,400-3,500 cr revenue guidance

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.